Literature DB >> 27041061

Thrombotic microangiopathy: Caplacizumab accelerates resolution of acute acquired TTP.

Bernhard Lämmle1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27041061     DOI： 10.1038/nrneph.2016.47

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  9 in total

1.  Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.

Authors:  Cui Jian; Juan Xiao; Lingjie Gong; Christopher G Skipwith; Sheng-Yu Jin; Hau C Kwaan; X Long Zheng
Journal:  Blood       Date:  2012-01-30       Impact factor: 22.113

2.  Plasma exchange complications in patients treated for thrombotic thrombocytopenia purpura-hemolytic uremic syndrome: 2011 to 2014.

Authors:  Rebekah S McClain; Deirdra R Terrell; Sara K Vesely; James N George
Journal:  Transfusion       Date:  2014-12       Impact factor: 3.157

3.  Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura.

Authors:  Filip Callewaert; Jan Roodt; Hans Ulrichts; Thomas Stohr; Walter Janse van Rensburg; Seb Lamprecht; Stefaan Rossenu; Sofie Priem; Wouter Willems; Josefin-Beate Holz
Journal:  Blood       Date:  2012-09-04       Impact factor: 22.113

4.  Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura.

Authors:  J L Moake; C K Rudy; J H Troll; M J Weinstein; N M Colannino; J Azocar; R H Seder; S L Hong; D Deykin
Journal:  N Engl J Med       Date:  1982-12-02       Impact factor: 91.245

5.  Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.

Authors:  G A Rock; K H Shumak; N A Buskard; V S Blanchette; J G Kelton; R C Nair; R A Spasoff
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

6.  Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.

Authors:  Flora Peyvandi; Marie Scully; Johanna A Kremer Hovinga; Spero Cataland; Paul Knöbl; Haifeng Wu; Andrea Artoni; John-Paul Westwood; Magnus Mansouri Taleghani; Bernd Jilma; Filip Callewaert; Hans Ulrichts; Christian Duby; Dominique Tersago
Journal:  N Engl J Med       Date:  2016-02-11       Impact factor: 91.245

7.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.

Authors:  G G Levy; W C Nichols; E C Lian; T Foroud; J N McClintick; B M McGee; A Y Yang; D R Siemieniak; K R Stark; R Gruppo; R Sarode; S B Shurin; V Chandrasekaran; S P Stabler; H Sabio; E E Bouhassira; J D Upshaw; D Ginsburg; H M Tsai
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

8.  von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.

Authors:  M Furlan; R Robles; M Galbusera; G Remuzzi; P A Kyrle; B Brenner; M Krause; I Scharrer; V Aumann; U Mittler; M Solenthaler; B Lämmle
Journal:  N Engl J Med       Date:  1998-11-26       Impact factor: 91.245

9.  Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis.

Authors:  M Furlan; R Robles; B Lämmle
Journal:  Blood       Date:  1996-05-15       Impact factor: 22.113
  9 in total
  4 in total

Review 1.  ADAMTS13 conformations and mechanism of inhibition in immune thrombotic thrombocytopenic purpura.

Authors:  Konstantine Halkidis; X Long Zheng
Journal:  J Thromb Haemost       Date:  2022-08-03       Impact factor: 16.036

Review 2.  Platelets and platelet adhesion molecules: novel mechanisms of thrombosis and anti-thrombotic therapies.

Authors:  Xiaohong Ruby Xu; Naadiya Carrim; Miguel Antonio Dias Neves; Thomas McKeown; Tyler W Stratton; Rodrigo Matos Pinto Coelho; Xi Lei; Pingguo Chen; Jianhua Xu; Xiangrong Dai; Benjamin Xiaoyi Li; Heyu Ni
Journal:  Thromb J       Date:  2016-10-04

Review 3.  Clinical Efficacy and Safety Profile of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.

Authors:  Muhammad Haisum Maqsood; Kinza Rubab; Muhammad Zaigham Maqsood
Journal:  Cureus       Date:  2019-07-29

4.  Caplacizumab for Acute Thrombotic Thrombocytopenic Purpura.

Authors:  Katherine V Katsivalis; Jamie Thomas
Journal:  J Adv Pract Oncol       Date:  2021-03-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.